{
}
Goldman Sachs analysts have identified stocks that provide stability and visibility amid global market uncertainty, highlighting companies like PepsiCo, Waste Management, and Travelers for their low volatility and strong financial returns. They also point to high-growth stocks such as Live Nation and Spotify, while recommending income-focused investments like Bank of America and Schlumberger for their strong dividend potential. Conversely, stocks like Lazard and Marsh & McLennan may face earnings vulnerabilities.
Wall Street analysts are optimistic about CRISPR Therapeutics, projecting potential gains of 114% to 152% by 2025, driven by its gene therapy Casgevy and promising trial results for CTX112, a treatment for blood cancers. However, slow sales of Casgevy and significant operational losses raise concerns about the company's financial stability. Investors should weigh the high risks against potential rewards before committing funds.
Wall Street analysts are optimistic about CRISPR Therapeutics, projecting potential gains of 114% to 152% in 2025, driven by its gene therapy, Casgevy, which recently received FDA approval for treating sickle cell disease and beta-thalassemia. However, despite the promising technology, the company faces challenges in generating sales and manufacturing personalized treatments. Analysts have adjusted price targets, with one lowering it to $85 while maintaining a buy rating, and another setting a target of $100.
CRISPR Therapeutics, trading at $39.69 with a market cap of $3.39 billion, is focusing on the launch of its gene-based medicine CASGEVY® and advancing its gene editing pipeline. The company reported operating expenses of $110.1 million and a cash position of $1.94 billion, while analysts hold mixed ratings. Key developments include ongoing clinical trials for CTX112™ and CTX131™, with updates expected in 2025, alongside a strong demand for CASGEVY® following its regulatory approval for sickle cell disease and beta thalassemia.
CRISPR Therapeutics is expanding its CTX112 trial to include patients with systemic sclerosis and inflammatory myositis, with updates expected in mid-2025. The company is also advancing its gene-edited CAR T therapy targeting GPC3 for solid tumors, with a clinical trial set to begin in early 2025. Additionally, significant progress is being made in cardiovascular gene editing and regenerative medicine, with multiple updates anticipated throughout 2025.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison's expertise in clinical development is expected to enhance the company's innovative gene-based medicine initiatives. CRISPR Therapeutics, which celebrated the approval of the first CRISPR-based therapy in 2023, continues to advance its diverse portfolio targeting serious diseases.
[SEC](https://www.sec.gov) or [Bloomberg]
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, including leadership roles at AstraZeneca and Pfizer, Morrison's expertise in clinical development is expected to enhance the company's innovative pipeline. He has overseen the development of notable drugs such as Tagrisso®, Imfinzi®, and Lynparza®.
Vertex Pharmaceuticals has partnered with Orna Therapeutics, investing $65 million to develop next-gen gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. This collaboration allows Orna to expand its research capabilities and leverage its lipid nanoparticle delivery technology, aiming to create accessible treatments that bypass traditional cell therapy limitations. Vertex's recent FDA approvals for gene therapies in these areas further enhance the significance of this partnership.
Vertex Pharmaceuticals has entered a three-year partnership with Orna Therapeutics to advance in vivo gene therapies for sickle cell disease and beta thalassemia. The collaboration includes an upfront payment of $65 million, with potential milestone payments totaling up to $635 million. This initiative aims to enhance gene editing delivery methods, potentially eliminating the need for toxic preconditioning and streamlining the treatment process.
Vertex Pharmaceuticals Inc
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Goldman Sachs highlights stable stocks amid global market uncertainty
Peruvian Sol
Waste Management, Inc.
Commercial Metals Company
A. O. Smith Corporation
DraftKings Inc.
e.l.f. Beauty, Inc.
Sprouts Farmers Market, Inc.
Xcel Energy Inc.
Canadian Natural Resources Ltd
Live Nation Entertainment, Inc.
Newmark Group, Inc.
Bank of America Corporation
Atlassian Corp
Cenovus Energy Inc.
Spotify Technology S.A.
Tradeweb Markets Inc.
BAXTER INTERNATIONAL
Schlumberger Ltd
INTUIT
S&P Global Inc.
Marsh & McLennan Companies, Inc.
Vertex Pharmaceuticals Inc
Lazard, Inc.
Belden Inc.
PepsiCo, Inc.
Lennox International Inc.
USA
CAN
Show more
13:56 18.03.2025
analysts predict significant gains for crisper therapeutics amid challenges ahead
10:34 14.01.2025
biotech stock poised for significant gains amid challenges in treatment sales
10:34 14.01.2025
CRISPR Therapeutics sets ambitious 2025 goals amid strong market presence
United States Dollar
Vertex Pharmaceuticals Inc
CRISPR Therapeutics AG
CHE
Briggs Morrison
Samarth Kulkarni
13:10 13.01.2025
crispr therapeutics advances gene editing therapies for various diseases
13:02 13.01.2025
CRISPR Therapeutics nominates Briggs Morrison for Board of Directors position
14:00 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors appointment
14:00 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors election
United States Dollar
Vertex Pharmaceuticals Inc
AstraZeneca PLC
Bayer AG
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Merck & Co., Inc.
CHE
Briggs Morrison
Samarth Kulkarni
Show more
14:00 07.01.2025
vertex partners with orna therapeutics to advance gene therapies for blood disorders
13:00 07.01.2025
vertex partners with orna to advance in vivo gene editing therapies
01:00 07.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Finance Mergers & Acquisitions
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Central Bank Actions
Industry Mergers & Acquisitions
Inflation and Monetary Impact
CEO Changes
Market Analysis and Predictions
Government Economic Policies
Government Policies
Domestic Politics
Workplace Trends
GDP Growth & Recession Forecasts
Supply Chain Management
Countries:
Companies:
Barclays PLC
Apple Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Deutsche Bank Money Market PP
Banco Santander, S.A.
The Goldman Sachs Group, Inc.
Credit Suisse Strategic Income I
Berkshire Hathaway Inc.
Lloyds Banking Group plc
SpaceXCoin USD
Bank of America Corporation
Amazon.com, Inc.
UBS Group AG
Morgan Stanley
NVIDIA Corporation
Wells Fargo & Company
BNP Paribas SA
Commerzbank AG
UniCredit S.p.A.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Chinese Yuan
Canadian Dollar
Vietnamese Đồng
South Korean Won
Australian Dollar
Thai Baht
New Taiwan Dollar
Singapore Dollar
Indonesian Rupiah
Mexican Peso
Cambodian Riel
Russian Ruble
Hong Kong Dollar
Offshore Chinese Yuan
People:
Donald Trump
Elon Musk
Warren Buffett
JD Vance
Sergio Ermotti
Mark Haefele
Robin Leopold
Olivier Calvet
Troy L Rohrbaugh
Jennifer Piepszak
Karoline Leavitt
Ursula von der Leyen
Alex Kramm
Susan P. Crawford
Scott Bessent
Stacey Friedman
Jeff Bezos
George Saravelos
Francois Xavier Bouvignies
Joseph Spak